Articles tagged with Cancer Screening
A multidisciplinary panel of experts recommends evidence-based screening and surveillance strategies for pancreatic cancer in high-risk populations, aiming to improve early diagnosis and survival. The guidelines specify starting ages, surveillance intervals, imaging modalities, surgical indications, and lifestyle modifications.
This review highlights the regulatory roles of m6A in colorectal cancer, integrating oncogenic signaling and metabolic pathways. Key regulators include METTL3, METTL14, FTO, ALKBH5, and IGF2BP families, which control tumor growth, metastasis, immune evasion, and therapy resistance.
The University of Texas at San Antonio Health Science Center has received a grant from the American Cancer Society to implement HPV self-collection in primary care settings. The pilot aims to make cervical cancer screening more accessible for patients who face barriers to traditional screening.
A pilot study of the Participant Engagement Portal (PEP) tool shows that 84% of participants had a positive experience, with high usability and satisfaction rates. PEP facilitates two-way communication between patients and clinicians, allowing for self-reporting of social risk factors and future research opportunities.
A recent study found that melanoma disproportionately affects Florida's senior population, with older men experiencing twice as many skin cancer-related deaths as women. The study highlights gaps in prevention and early detection, particularly among men and non-Hispanic populations.
Researchers identified specific gene mutations and characteristics associated with early-onset breast cancer in young Black women. The study highlights the importance of genetic testing for this population, which faces lower screening rates than other groups.
A comprehensive review of breast cancer risk models in women with a family history found that none are highly accurate at identifying which women will develop the disease. The BOADICEA model showed balanced performance, while others had significant limitations, emphasizing the need for continued improvement.
The American Cancer Society has updated its guidelines for colorectal cancer screening, introducing blood-based and at-home stool testing options to increase accessibility. The new recommendations aim to close the screening gap and detect more cancers at an earlier stage, with a focus on underserved populations.
The American Cancer Society has endorsed two new types of stool tests and recommends limiting the use of blood tests for colorectal cancer screening. The guidelines aim to encourage people to get screened while improving detection rates.
A Kaiser Permanente study found that HPV self-collection increased cervical cancer screening completion by 2.2% among over 95,000 members, with higher gains in diverse populations. The program also reduced clinician-performed pelvic exams and improved follow-up for high-risk HPV results.
Lanthanide nanoprobes have improved signal-to-noise ratio, enabling ultrasensitive detection of cancer biomarkers and visual identification of cancer cells. The nanoparticles maintain stable luminescence across a wide pH range and in simulated human body fluids, ensuring reliable performance.
A team of Rice University bioengineers has developed a new way to create highly realistic mock patient samples that could help accelerate the development of faster and more accessible cervical cancer screening tests. The approach combines multiple factors, including viral DNA levels and cell counts, to mimic real clinical specimens.
Colleen Scott's patented research develops a shortwave infrared dye to visualize cancer cells, enabling safe and high-resolution deep tissue visualization. Her technology selectively targets cancer cells, allowing clinicians to identify tumor boundaries with greater precision.
Researchers found a sustained reduction in colorectal cancer incidence and death associated with single flexible sigmoidoscopy screening, particularly in men. The study suggests that this screening method can provide long-lasting benefits beyond the usual 15-year screening age range.
The ERASur clinical trial is investigating whether total ablative therapy can improve overall survival in patients with newly diagnosed, limited metastatic colorectal cancer. The study has reached one-third patient accrual milestone, signaling strong momentum.
The ASPIRE trial aims to enroll 1,200 participants with advanced prostate cancer and assess the impact of chemotherapy on overall survival and disease progression. Genetic profiling is included to identify patients who benefit most from intensified treatment.
The review highlights how retrieval-augmented generation can improve the accuracy, transparency, and clinical reliability of AI tools in cancer care. RAG-enhanced systems produced more accurate results than standard AI models across multiple studies.
A new survey found that nearly half of women incorrectly believe annual mammograms should start at age 50. Experts recommend yearly mammograms starting at age 40 for average-risk women. This delay can lead to cancers being found at a later stage, when treatment can be more complex.
The new NCCN Guidelines for Patients: Prostate Cancer Screening provide a comprehensive guide to evidence-based recommendations for age-specific screening. The guidelines aim to balance the benefits of early detection with the risks of unnecessary procedures, emphasizing the importance of personalized care and monitoring.
Researchers found that a newer stool-based screening test, FIT-DNA, increased completion rates among participants from community health centers. However, follow-up colonoscopy tests remained low, highlighting the need for continued support and access to diagnostic services.
A new study found that prostate cancer overdiagnosis increases with age, with low rates in younger men and high rates in older men. The study suggests that targeted PSA testing or screening policies for men in their 50s and early 60s may be more effective.
Researchers have identified the Prrx1 gene as a key regulator of metastatic potential in breast cancer tumors. This discovery helps explain why highly invasive cells do not always give rise to metastases, and how cells combine invasiveness and proliferation to become the most dangerous from a clinical perspective.
A study by the Alliance Foundation Trials shows that combining immunotherapy and chemotherapy before surgery can help more patients with locally advanced non-small cell lung cancer undergo complete cancer resection, improving their long-term health. The treatment also led to high rates of lymph node clearance and successful surgical re...
A national study found that unmet health-related social needs are associated with lower colorectal cancer screening rates, particularly among adults aged 50-64. Addressing these needs may support age-specific strategies to improve screening rates.
UCLA investigators present new research on targeted drug delivery for colorectal cancer, COVID-19's impact on breast cancer outcomes, and AI in cancer diagnosis. These studies offer insights into overcoming drug resistance, enhancing immune responses, and improving outcomes for patients with difficult-to-treat cancers.
Adults aged 75 or older without adenoma on prior colonoscopy have lower risk of subsequent colorectal cancer and CRC death. Despite this, those with prior adenoma may consider deprioritizing surveillance colonoscopy relative to other health concerns.
A new article in JMIR Publications showcases precision oncology's success, where individualized multi-drug regimens improve treatment responses and survival rates for patients with advanced cancers. The study found that closely matching drug therapies to tumor mutations leads to better outcomes, while also offering a safer profile.
A new, cost-effective blood test detects liver, lung, ovarian, stomach cancers, and various non-cancer conditions by analyzing DNA fragments in the bloodstream. The test achieved high accuracy rates for multi-cancer detection and tissue-of-origin identification.
A recent study published in the Journal of General Internal Medicine found that women with diabetes are less likely to receive recommended preventive care services such as conception counseling and breast/cervical cancer screening. This oversight puts them at risk for preventable medical conditions like pregnancy complications.
A new study in China finds that onetime lowdose computed tomography (LDCT) screening can significantly reduce lung cancer mortality in a non–risk based population, including individuals with no smoking history. The findings support reconsideration of current eligibility criteria.
Researchers have reported early, reassuring results from the LORD trial on active surveillance for low-risk DCIS. The study found that patients with active surveillance did not experience worse early outcomes compared to those who underwent immediate surgery, and that many chose active surveillance over surgery.
A minimally invasive liquid biopsy test has been shown to diagnose Burkitt lymphoma rapidly and accurately in sub-Saharan Africa, where delays in traditional testing often prove fatal. The test achieved an overall accuracy of 98% and reduced the time needed to reach a diagnosis by 40 days on average.
Researchers compare prostate cancer screening to breast cancer screening, finding similarities in identifying significant cancers and reducing mortality. The study suggests that prostate cancer screening should be reconsidered, offering benefits over harms, and highlights the need for further analysis on costs.
A new imaging test, PSMA PET/CT scan, has been shown to safely reduce the number of biopsies needed for suspected prostate cancer, with no harm to patients. The PRIMARY2 trial found that the scan could identify low-risk patients who did not need a biopsy, while targeting suspicious areas for those who did.
Research presented at EAU26 confirms that prostate cancer screening leads to a reduction in mortality, but also detects cancers that would otherwise remain undetected. The study's findings suggest that using MRI in prostate cancer screening can reduce overdiagnosis and unnecessary biopsies.
Severe COVID-19 and influenza infections can prime the lungs for cancer development, according to new research. Vaccination, however, largely prevents these changes, suggesting a reduced risk of lung cancer.
The King Center for Lynch Syndrome will advance research, outreach, education, and patient care for Lynch syndrome, a hereditary condition affecting 1 in 279 individuals. The center will provide cutting-edge research, life-long comprehensive care, and increased awareness for patients and families affected by Lynch syndrome.
New research warns that popular AI systems for predicting cancer biology may rely on visual shortcuts, raising concerns about their reliability for real-world patient care. Despite achieving high accuracy, these models often fail when conditions change or confounding factors are controlled.
Renowned cancer clinician Dr. Daniela Matei will lead the Houston Methodist Dr. Mary and Ron Neal Cancer Center, bringing expertise in ovarian cancer treatment and therapeutics. She aims to bridge laboratory science to the clinic, advancing new concepts from bench to bedside.
A new fecal SDC2 methylation assay, combined with the Asia-Pacific Colorectal Screening Scoring (APCS), demonstrates superior performance in detecting advanced adenomas and stratifying risk. The test's high specificity makes it a valuable tool for prioritizing colonoscopy.
Researchers at Linköping University have developed an AI-boosted electronic nose that can detect ovarian cancer from blood plasma samples with high accuracy. The method uses machine learning to identify patterns specific to the disease, making it a promising tool for early detection and improved survival rates.
Researchers found that both screening methods lead to more cases of early-stage cancer being detected, especially in the first two years. The study suggests that screening may have a preventive effect by removing precursors to cancer.
A recent clinical trial found that remote telehealth services increased the uptake of genetic counseling and testing in adult survivors of childhood cancers. The study showed a significant impact on reducing morbidity and mortality by driving earlier detection of subsequent cancer.
A new review highlights the growing burden of lung cancer in never-smokers, emphasizing the need for dedicated research, screening, and clinical trials. The study argues that LCINS has distinct causes and biology requiring a different approach to diagnosis and treatment.
A new AI-powered analysis tool called PROVIZ is being tested in Norwegian hospitals to diagnose prostate cancer. The tool helps doctors determine which patients need a biopsy, reducing the number of unnecessary procedures.
A new study suggests that women vaccinated against human papillomavirus (HPV) may only need cervical cancer screenings 2-3 times over a lifetime, without compromising health benefits. This approach could lead to cost-effectiveness and reduced unnecessary follow-up procedures.
Researchers have developed a four-marker panel that can detect early-stage pancreatic cancer with high accuracy, potentially improving survival rates. The new test distinguishes cancer patients from healthy individuals and those with non-cancerous conditions, such as pancreatitis.
A new liquid biopsy technology, Bridge Capture, has been developed to overcome the challenges of sensitive and cost-efficient cancer diagnostics. It detects rare variant allele frequencies with superior sensitivity compared to existing methods.
A new long-term prediction tool estimates the risk of dying from prostate cancer by combining PSA levels with factors like family history, race, age, and other health conditions. The tool showed higher accuracy in predicting prostate cancer death over decades compared to existing models.
A recent study published in Gut journal revealed that Streptococcus anginosus produces methionine metabolites, which significantly contribute to the development of gastric cancer. The research opens new paths for microbiota-targeted prevention strategies.
A new clinical trial, RECIPROCAL, seeks to optimize targeted radiation therapy for men with advanced prostate cancer by adjusting treatment based on individual PSA levels. The trial aims to minimize side effects while preserving survival benefits.
A new study has validated a non-destructive method to detect 'forever chemicals' on protective equipment, reducing the risk of cancer to firefighters. Researchers found PFAS in every set of firefighter gear examined, including breathing masks, with concentrations reaching hundreds of nanograms per gram.
A recent review suggests that Clostridioides difficile infection may promote the development of gastrointestinal tumors, including colorectal cancer. The bacterium's toxins can cause damage to the epithelial cytoskeleton and induce inflammation, leading to chronic colitis and increased risk of CRC.
A community awareness campaign in Nigeria increased awareness of colorectal cancer symptoms and risk factors, leading to earlier detection of the disease. The program also identified precancerous polyps and detected colorectal cancer at curable stages.
Researchers developed a new compact Raman imaging system that can differentiate between tumor and normal tissue, offering a promising route to earlier cancer detection. The system uses special SERS nanoparticles to detect faint signals from tumor markers, highlighting spots likely to contain tumor tissue.
The grant aims to increase individual screenings and change how health systems embed evidence-based screening practices into everyday operations. PA-CARES will work with trusted organizations in 28 counties with the lowest screening rates to implement effective screening options and facilitate timely linkage to care.
Researchers have developed a simple urine test that can effectively diagnose and stage bladder cancer using cell-free DNA fragmentation analysis. The study found that specific patterns of cfDNA fragmentation can identify muscle-invasive bladder cancer with excellent specificity and predictive value.
Researchers at MD Anderson have made significant discoveries in the treatment of rare bile duct cancers, with zanidatamab showing promising results. Additionally, a study identified RASH3D19 as a target to overcome treatment resistance in KRAS-mutant cancers.